ALZ-801 Enters Open-Label Studies, Subcutaneous Ocrelizumab Gets Positive EU Recommendation, FDA Approves Sprinkle Formulation of Valbenazine
SAGE-718 Fails Phase 2 Study, Foralumab Dampens Microglial Activation, MDA and FARA Collaborate on Gene Therapy Studies
Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS
Advancing MS Care for Minority Populations Using the VISIBL-MS Bilingual Framework: Jaime Imitola, MD